GLP-1 Decade Reshape
Reva Jariwala@reva_jariwala
+6.1%
since Sep 30
The idea
I believe GLP-1 drugs will keep spreading over the next decade and reshape far more than pharmacy sales. This basket owns the drugmakers themselves alongside three downstream layers: the supply chain of injectors and vials every dose needs, the healthcare companies distributing and treating around the drugs, and the consumer brands benefiting as eating and spending habits shift. It's weighted for slow structural change rather than a quick trade, spread across many names instead of concentrated bets, with a modest cash buffer kept on the side.
What it owns
- The companies making the drugs themselves anchor this shift, capturing the largest share of a decade-long expansion in treatment. · Eli LillyIts Zepbound and Mounjaro are the fastest-growing GLP-1 drugs, capturing the largest share if prescription growth continues through the decade., Novo NordiskIt built the GLP-1 category with Ozempic and Wegovy and maintains substantial market share, holding up if manufacturing scale and pipeline stay competitive., AmgenIts MariTide monthly injection aims to beat weekly GLP-1s on convenience, representing a second-generation drug if trial data stays strong., AstraZenecaIt is pursuing the oral GLP-1 pill format, which could extend treatment to far more people than injections if trials advance., Viking TherapeuticsIts obesity drug data rivals the giants, offering high-risk exposure to a biotech that could either post competitive results or draw acquisition.28%
- People on these drugs eat, dress and exercise differently, creating spending patterns that benefit companies aligned with those new habits. · BellRing BrandsIts Premier Protein shakes address the muscle-protection need for people eating less on GLP-1s, benefiting if protein shake sales grow with drug adoption., TJX CompaniesIts off-price stores capture wardrobe churn from millions of people dropping sizes and replacing clothes on a budget., Simply Good FoodsIts Quest and Atkins brands are built for the high-protein, smaller-appetite eating pattern that GLP-1 users adopt., Sprouts Farmers MarketIt is the grocer built around fresh and protein categories, the direction eating habits shift as GLP-1 use grows., Planet FitnessIt is the cheapest entry into a gym, where users go to preserve muscle while losing weight on GLP-1s.23%
- Distributing, prescribing and treating around GLP-1s creates winners in healthcare infrastructure and specialized services beyond the drugmakers. · McKessonIt distributes a huge share of US prescription drugs, with GLP-1s now a major volume driver, earning fees on each growing prescription., CencoraIt is the second major prescription drug distributor, doubling the take's exposure to the same GLP-1 script volume wave., Hims & Hers HealthIt is how many people access GLP-1s through phone-based prescriptions, benefiting if telehealth stays a legal and growing channel., StrykerIt sells hip and knee replacements to patients who become eligible for surgery after losing weight on GLP-1s., DexcomIts glucose monitors ride the metabolic health attention GLP-1s created, benefiting if adoption grows alongside drug use rather than replacing it.21%
- Every dose requires injectors, glass, needles and manufacturing capacity, creating a toll on the supply chain regardless of which drug wins. · West Pharmaceutical ServicesIt makes the elastomer components and injector parts inside GLP-1 pens, earning a toll on every dose regardless of which drug wins., Thermo Fisher ScientificIt runs the fill-finish lines that put GLP-1 drugs into pens and vials, with drugmakers paying to reserve capacity that runs at full utilization., Stevanato GroupIt supplies the glass cartridges and pen systems drugmakers fill, collecting a toll on every dose as pen demand outpaces production capacity., Becton DickinsonIt makes pen needles by the billions, an unavoidable cost on every injection that benefits from injectable GLP-1 growth.20%
- Cash8%